

## Special Issue

# Vaccine Adjuvants Targeting Emerging and Re-emerging Livestock Infectious Disease: Boosting Stronger Immune Responses

### Message from the Guest Editors

Emerging and re-emerging infectious diseases caused by viruses, bacteria, fungi and parasites are causing significant morbidity and mortality not only in humans, but also in various livestock, including cattle, pigs, sheep, birds, and others. Among numerous strategies, vaccination is the most effective approach to preventing and controlling infectious diseases. In most cases, vaccines need a suitable adjuvant and delivery carrier to trigger an adequate immune response. However, the availability of veterinary vaccine adjuvants and carriers is limited. Therefore, it is urgent to formulate novel strategies to develop safe and efficient adjuvants and vaccine delivery carriers to control various animal infectious diseases. The aim of this Special Issue is to present research on the development and understanding of novel adjuvants and vaccine delivery carriers for emerging and re-emerging infectious diseases in various livestock. The following research themes are welcome:

- Novel adjuvants for veterinary vaccines
- Novel vaccine delivery carriers
- Understanding the underlying molecular mechanisms of novel vaccine adjuvants and delivery carriers

### Guest Editors

Prof. Dr. Wei Xu

Prof. Dr. Kai Zhao

Prof. Dr. Huichen Guo

### Deadline for manuscript submissions

closed (31 August 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/182762](https://mdpi.com/si/182762)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).